NK cell ther­a­py-fo­cused biotech eyes SPAC deal

A small, San­ta Ana-based biotech cre­at­ed in 2017 is look­ing to en­ter a SPAC deal as it lays out plans to be­gin tri­als in its lead cell ther­a­py can­di­dates and bring on new ex­ec­u­tives.

Graf Ac­qui­si­tion Corp. IV and NKGen Biotech an­nounced Thurs­day, with few oth­er de­tails, that the two com­pa­nies signed a non-bind­ing let­ter of in­tent to “pur­sue a busi­ness com­bi­na­tion.” Graf Ac­qui­si­tion II and III with­drew their IPOs last year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN